Clinical trial NCT01052480 - References

Influenza A — Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

Citation(s)

•   Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG
  Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol. 1992 Feb;66(2):1129-38.
•   de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J
  Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005 Dec 22;353(25):2667-72.
•   Morse SS
  Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995 Jan-Mar;1(1):7-15. Review.

A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)

Details for clinical trial NCT01052480